Dion Gregory R, Teng Stephanie E, Achlatis Efstratios, Fang Yixin, Amin Milan R
1 NYU Voice Center, Department of Otolaryngology-Head and Neck Surgery, New York University School of Medicine, New York, New York, USA.
Otolaryngol Head Neck Surg. 2017 Jul;157(1):77-79. doi: 10.1177/0194599817703949. Epub 2017 May 2.
This study employs validated cough assessment tools to prospectively determine the impact of tramadol on cough severity and quality of life in subjects with neurogenic cough. The study was a prospective case series with planned data collection at a tertiary care academic medical center laryngology practice. Sixteen consecutive collected subjects with neurogenic cough prospectively completed pre- and posttreatment validated cough assessment tools, the cough severity index (CSI) and Leicester Cough Questionnaire (LCQ). All subjects in the study reported at least some improvement in their cough symptoms. In a Wilcoxon signed rank test that compared paired results, CSI scores improved from 23 to 14 and LCQ scores improved from 74 to 103 ( P = .003 and P = .005, respectively). This small preliminary assessment suggests that tramadol warrants additional evaluation as a treatment for neurogenic cough.
本研究采用经过验证的咳嗽评估工具，前瞻性地确定曲马多对神经源性咳嗽患者咳嗽严重程度和生活质量的影响。该研究是一个前瞻性病例系列，在一家三级医疗学术医学中心的喉科学实践中进行了计划的数据收集。连续收集的16名神经源性咳嗽患者前瞻性地完成了治疗前和治疗后经过验证的咳嗽评估工具，即咳嗽严重程度指数（CSI）和莱斯特咳嗽问卷（LCQ）。研究中的所有受试者均报告其咳嗽症状至少有一定改善。在比较配对结果的Wilcoxon符号秩检验中，CSI评分从23提高到14，LCQ评分从74提高到103（P分别为0.003和0.005）。这项小型初步评估表明，曲马多作为神经源性咳嗽的一种治疗方法值得进一步评估。
